P. Bonate

P. Bonate, D. Taft, A. Ajavon, 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Estimation of QT interval prolongation through model-averaging

P. Bonate, 2017, Journal of Pharmacokinetics and Pharmacodynamics.

Highlights and Book Reviews

P. Bonate, R. Bies, 2006 .

Methods and strategies for assessing uncontrolled drug–drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP) Working Group

Justin C. Earp, P. Bonate, M. Karlsson, 2016, Journal of Pharmacokinetics and Pharmacodynamics.

Clinical Trial Simulation in Drug Development

Peter L. Bonate, P. Bonate, 2000, Pharmaceutical Research.

Physiologically‐Based Pharmacokinetic Modeling for the Prediction of a Drug–Drug Interaction of Combined Effects on P‐glycoprotein and Cytochrome P450 3A

P. Bonate, Kanji Komatsu, M. Choules, 2020, CPT: pharmacometrics & systems pharmacology.

Determination of Cocaine in Biological Matrices Using Reversed Phase HPLC: Application to Plasma and Brain Tissue

P. Bonate, A. Swann, C. M. Davis, 1995 .

Pathophysiology and Pharmacokinetics Following Burn Injury

P. Bonate, 1990, Clinical pharmacokinetics.

Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days1, 3, and 5 Every 3 Weeks in Patientswith Advanced Solid Tumors

P. Bonate, D. Ryan, L. Appleman, 2005 .

Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors

P. Bonate, D. Ryan, L. Appleman, 2005, Clinical Cancer Research.

Clonazepam and sertraline: absence of drug interaction in a multiple-dose study.

P. Bonate, P. Kroboth, E. Suárez, 2000, Journal of clinical psychopharmacology.

Clinical and Pharmacokinetic Study of Clofarabine in Chronic Lymphocytic Leukemia: Strategy for Treatment

P. Bonate, W. Plunkett, M. Keating, 2006, Clinical Cancer Research.

Phase I and Pharmacokinetic Study of Tasidotin Hydrochloride (ILX651), a Third-Generation Dolastatin-15 Analogue, Administered Weekly for 3 Weeks Every 28 Days in Patients with Advanced Solid Tumors

P. Bonate, G. Weiss, A. Mita, 2006, Clinical Cancer Research.

Phase I and Pharmacokinetic Study ofTasidotin Hydrochloride ( ILX 651 ) , aThird-Generation Dolastatin-15 Analogue , AdministeredWeekly for 3 Weeks Every 28 Days in Patients with Advanced SolidTumors

P. Bonate, A. Mita, E. Rowinsky, 2006 .

Exposure–Response Analysis of Micafungin in Neonatal Candidiasis

P. Bonate, D. Kaufman, P. Smith, 2018, The Pediatric infectious disease journal.

Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study)

P. Bonate, W. Hope, L. Kovanda, 2016, Antimicrobial Agents and Chemotherapy.

Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints.

P. Bonate, T. Walsh, W. Hope, 2016, The Journal of antimicrobial chemotherapy.

P. Bonate, P L Bonate, 1991, Journal of clinical pharmacology.

Discovery and development of clofarabine: a nucleoside analogue for treating cancer

P. Bonate, S. Weitman, J. Secrist, 2006, Nature Reviews Drug Discovery.

Editor’s note on the themed issue: integration of machine learning and quantitative systems pharmacology

P. Bonate, 2022, Journal of pharmacokinetics and pharmacodynamics.

Editorial to themed issue: Recent advances in cardiovascular pharmacokinetic–pharmacodynamic modeling and simulation

P. Bonate, 2018, Journal of Pharmacokinetics and Pharmacodynamics.

Assessment of QTc Interval Prolongation in a Phase I Study Using Monte Carlo Simulation

P. Bonate, 2002 .

A Phase I Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously Daily for 5 Consecutive Days Every 3 Weeks in Patients with Advanced Solid Tumors

P. Bonate, E. Hersh, L. Hammond, 2005, Clinical Cancer Research.

APhase I Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously Daily for 5 Consecutive Days Every 3Weeks in Patientswith Advanced SolidTumors

P. Bonate, E. Hersh, L. Hammond, 2005 .

COVID-19: opportunity arises from a world health crisis

P. Bonate, 2020, Journal of Pharmacokinetics and Pharmacodynamics.

Controversies in Oncology: Size Based vs. Fixed Dosing

P. Bonate, 2016 .

A pharmacometrician’s role in enhancing medication use in pregnancy and lactation

P. Bonate, S. Quinney, 2020, Journal of Pharmacokinetics and Pharmacodynamics.

Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias.

P. Bonate, H. Kantarjian, W. Plunkett, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies

P. Bonate, S. Soignet, B. Hollis, 2003, Investigational New Drugs.

Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi

P. Bonate, D. Kowalski, L. Kovanda, 2016, Antimicrobial Agents and Chemotherapy.

Context-dependent cross-sensitization between cocaine and amphetamine.

P. Bonate, A. Swann, P. B. Silverman, 1996, Life sciences.

Book review: Patterson S, Jones B 2006: Bioequivalence and statistics in clinical pharmacology. Boca Raton, FL: Chapman & Hall/CRC, http://www.crcpress.com, xi, 374 pp., illustrations, $89.95

P. Bonate, 2007 .

Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.

E. Estey, P. Bonate, Z. Estrov, 2005, Blood.

Editorial to the themed issue on application of pharmacometrics to the development of drugs for rare diseases

P. Bonate, 2019, Journal of Pharmacokinetics and Pharmacodynamics.

Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males.

Peter L Bonate, P. Bonate, Simon Floret, 2004, British journal of clinical pharmacology.

Pharmacokinetics in mice implanted with xenografted tumors after intravenous administration of tasidotin (ILX651) or its carboxylate metabolite

P. Bonate, Roy D. Krumbholz, S. Schmid, 2007, The AAPS Journal.

Approximate confidence intervals in calibration using the bootstrap

Peter L. Bonate, P. Bonate, 1993 .

Extrapolation of praziquantel pharmacokinetics to a pediatric population: a cautionary tale

P. Bonate, J. Keiser, H. Burt, 2018, Journal of Pharmacokinetics and Pharmacodynamics.

Two heads are better than one: current landscape of integrating QSP and machine learning

P. Bonate, I. Androulakis, T. Helikar, 2022, Journal of Pharmacokinetics and Pharmacodynamics.

Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi

P. Bonate, S. Mujais, D. Andes, 2017, Antimicrobial Agents and Chemotherapy.

Safety, Tolerability, and Pharmacokinetics of Eliglustat Tartrate (Genz‐112638) After Single Doses, Multiple Doses, and Food in Healthy Volunteers

P. Bonate, D. Mathews, L. Blankstein, 2011, Journal of clinical pharmacology.

A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1.

P. Bonate, D. Rosenthal, G. Pastores, 2010, Blood.

Drug Interactions at the Renal Level

P. Bonate, S. Weir, K. Reith, 1998, Clinical pharmacokinetics.

Pharmacokinetic-Pharmacodynamic Modeling And Simulation

Peter L. Bonate, P. Bonate, 2005 .

Nonlinear Mixed Effects Models: Practical Issues

Peter L. Bonate, P. Bonate, 2011 .

Plasma and Cerebrospinal Fluid Pharmacokinetics of Clofarabine in Nonhuman Primates

P. Bonate, J. Nuchtern, S. Berg, 2005, Clinical Cancer Research.

Pharmacokinetics

P. Bonate, Peter L. Bonate, 2011 .

Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinoma

Peter L. Bonate, P. Bonate, A. Suttle, 2013, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics of a Pediatric Tribendimidine Dose-Finding Study To Treat Hookworm Infection in African Children

P. Bonate, J. Keiser, J. Coulibaly, 2018, Antimicrobial Agents and Chemotherapy.

A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development

P. Bonate, D. Yin, D. Bottino, 2023, Journal of Pharmacokinetics and Pharmacodynamics.

Population Pharmacokinetics of Clofarabine, a Second‐Generation Nucleoside Analog, in Pediatric Patients With Acute Leukemia

P. Bonate, W. Plunkett, V. Gandhi, 2004, Journal of clinical pharmacology.

Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response.

P. Bonate, J. Kuhlmann, D. Mould, 2007, British journal of clinical pharmacology.

Wet granulation fine particle ethylcellulose tablets: Effect of production variables and mathematical modeling of drug release

P. Bonate, S. Neau, Anjali Agrawal, 2003, AAPS PharmSci.

Linear Mixed Effects Models

P. Bonate, 2011 .

Plasma and cerebrospinal fluid pharmacokinetics of tasidotin (ILX-651) and its metabolites in non-human primates

P. Bonate, J. Nuchtern, S. Berg, 2009, Cancer Chemotherapy and Pharmacology.

Intracellular Activation and Deactivation of Tasidotin, an Analog of Dolastatin 15: Correlation with Cytotoxicity

P. Bonate, T. Copeland, E. Hamel, 2009, Molecular Pharmacology.

The Art of Modeling

Peter L. Bonate, P. Bonate, 2011 .

Factors affecting species differences in the kinetics of metabolites of trichloroethylene.

P. Bonate, M. Templin, D. Stevens, 1995, Journal of toxicology and environmental health.

Phase I trial of tirapazamine and cyclophosphamide in children with refractory solid tumors: a pediatric oncology group study.

P. Bonate, N. Winick, M. Bernstein, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Modeling and Simulation in the Translational Pharmacology of CNS Drugs

P. Bonate, E. D. Lange, 2019, Translational Medicine in CNS Drug Development.

Effect of Censoring Due to Progressive Disease on Tumor Size Kinetic Parameter Estimates

P. Bonate, B. Suttle, 2013, The AAPS Journal.

Pharmacokinetics and Immunogenicity of ASP0113 in CMV‐Seronegative Dialysis Patients and CMV‐Seronegative and ‐Seropositive Healthy Subjects

Larry R. Smith, P. Bonate, C. Van Sant, 2020, Clinical pharmacology in drug development.

Population pharmacokinetics of immediate‐ and prolonged‐release tacrolimus formulations in liver, kidney and heart transplant recipients

P. Bonate, J. Keirns, Zheng Lu, 2019, British journal of clinical pharmacology.

Chromatographic Calibration Revisited

P. Bonate, 1990 .

Uptake and biodisposition of 2‐ylcyanamide‐1,3,4‐thiadiazole (LY217896) by red blood cells

P. Bonate, Albert Peyton, 1995, Biopharmaceutics & drug disposition.

Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer

P. Bonate, P. Steinherz, P. Gaynon, 2011, Cancer Chemotherapy and Pharmacology.

Scientific white paper on concentration-QTc modeling

Georg Ferber, Christine Garnett, Peter L Bonate, 2017, Journal of Pharmacokinetics and Pharmacodynamics.

Effect of assay measurement error on parameter estimation in concentration–QTc interval modeling

Peter L Bonate, P. Bonate, 2013, Pharmaceutical statistics.

The application of extreme value theory to pharmacometrics

P. Bonate, 2020, Journal of pharmacokinetics and pharmacodynamics.

Correction to: Scientific white paper on concentration-QTc modeling

Georg Ferber, Christine Garnett, Peter L Bonate, 2018, Journal of Pharmacokinetics and Pharmacodynamics.

Preliminary physiologically based pharmacokinetic model for cocaine in the rat: model development and scale-up to humans.

P L Bonate, P. Bonate, A. Swann, 1996, Journal of pharmaceutical sciences.

Effect of correlation on covariate selection in linear and nonlinear mixed effect models

P. Bonate, 2017, Pharmaceutical statistics.

Prospective Allometric Scaling: Does the Emperor Have Clothes?

P L Bonate, D Howard, P. Bonate, 2000, Journal of clinical pharmacology.

Critique of Prospective Allometric Scaling: Does the Emperor Have Clothes?

P. Bonate, D. Howard, 2000, Journal of clinical pharmacology.

Conversion of the anti-tumor agent tasidotin (ILX651) to its active metabolite by prolyl oligopeptidase

P. Bonate, P. Jurutka, Roy D. Krumbholz, 2010 .

Animal models for studying transport across the blood-brain barrier

Peter L. Bonate, P. Bonate, 1995, Journal of Neuroscience Methods.

Principles of Simulation

Peter L. Bonate, P. Bonate, 2011 .

Guidelines for the Quality Control of Population Pharmacokinetic–Pharmacodynamic Analyses: an Industry Perspective

P. Bonate, S. Tannenbaum, A. Yassen, 2012, The AAPS Journal.

Clinical pharmacology of the antibody-drug conjugate enfortumab vedotin in advanced urothelial carcinoma and other malignant solid tumors.

P. Bonate, J. Rosenberg, T. Kadokura, 2022, Journal of Clinical Oncology.

QTc interval analysis—an ever-evolving endeavor

P. Bonate, 2021, Journal of Pharmacokinetics and Pharmacodynamics.

Abstract B6: A phase II study of the efficacy and safety of foretinib, a novel receptor tyrosine kinase inhibitor, given on an intermittent 5‐days‐on/9‐days‐off (5/9) schedule in patients with recurrent or metastatic squamous cell cancer of the head and neck

P. Bonate, T. Seiwert, S. Swann, 2009 .

Methods and strategies for assessing uncontrolled drug–drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP) Working Group

Justin C. Earp, P. Bonate, M. Karlsson, 2016, Journal of Pharmacokinetics and Pharmacodynamics.

Nonlinear Mixed Effects Modeling in Systems Pharmacology

Zheng Lu, Peter L. Bonate, Stacey Tannenbaum, 2016 .

Peter L. Bonate, P. Bonate, 2005, The AAPS Journal.

Guidelines for the Quality Control of Population Pharmacokinetic–Pharmacodynamic Analyses: an Industry Perspective

P. L. Bonate, A. Strougo, A. Desai, 2012, The AAPS Journal.

Assessment of QTc Prolongation for Non‐Cardiac‐Related Drugs from a Drug Development Perspective

P. Bonate, Tanya L. Russell, 1999, Journal of clinical pharmacology.

Case Studies in Linear and Nonlinear Modeling

P. Bonate, 2011 .

THE DISTRIBUTION, METABOLISM, AND ELIMINATION OF CLOFARABINE IN RATS

P. Bonate, J. Q. Rose, P. Yerino, 2005, Drug Metabolism and Disposition.

Coverage and Precision of Confidence Intervals for Area Under the Curve Using Parametric and Non-parametric Methods in a Toxicokinetic Experimental Design

P. Bonate, 1998, Pharmaceutical Research.

The effects of active metabolites on parameter estimation in linear mixed effect models of concentration–QT analyses

P. Bonate, 2013, Journal of Pharmacokinetics and Pharmacodynamics.

A Comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors

P. Bonate, P. LoRusso, R. Kurzrock, 2012, Investigational New Drugs.

Modeling Tumor Growth in Oncology

Peter L. Bonate, P. Bonate, 2011 .

Simulation studies on the estimation of total area under the curve in the presence of right-tailed censoring

Peter L. Bonate, P. Bonate, 2014, Journal of Pharmacokinetics and Pharmacodynamics.

A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1.

P. Bonate, D. Rosenthal, G. Pastores, 2010, Blood.

Training the next generation of pharmacometric modelers: a multisector perspective.

P. Bonate, B. Corrigan, M. Neely, 2023, Journal of pharmacokinetics and pharmacodynamics.

Comprar Pharmacokinetic-pharmacodynamic modeling and simulation | P. Bonate | 9781441938961 | Springer

P. Bonate, P. Bonate, 2011 .

Nonlinear Mixed Effects Models: Case Studies

Peter L. Bonate, P. Bonate, 2011 .

Covariate Distribution Models in Simulation

Peter L. Bonate, P. Bonate, 2011 .

Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates.

P. Bonate, M. Jamei, R. Rose, 2023, Journal of Pharmacokinetics and Pharmacodynamics.

Intracellular Activation and Deactivation of Tasidotin, an Analog of Dolastatin 15: Correlation with Cytotoxicity

P. Bonate, T. Copeland, E. Hamel, 2009, Molecular Pharmacology.

Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints.

P. Bonate, T. Walsh, W. Hope, 2016, The Journal of antimicrobial chemotherapy.

Musings on the current state of COVID-19 modeling and reporting

P. Bonate, 2020, Journal of Pharmacokinetics and Pharmacodynamics.